SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to a significant surge in price and trading volume, leading to multiple trading halts. The community is focused on its potential for after-hours gains, drawing comparisons to other recent low-float runners. Discussions revolve around holding strong and anticipating a continued upward trajectory, with some cautioning about potential volatility.

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex Inc. ($CETX) is trending as traders discuss its potential for a multi-day run and a possible short squeeze, drawing comparisons to other recent high-flying small-float stocks. Community members are actively trading the stock, citing its high trading volume and potential for significant after-hours movement. The stock's volatility and potential for further gains are key talking points among investors.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss the potential impact of upcoming 48-week data and a recent FDA policy change that could expedite drug approvals. Community members are debating the significance of statistical improvements and speculating on potential buyout scenarios, comparing ALT's potential to competitors in the MASH and weight loss space. Bullish sentiment revolves around best-in-class potential, while bears cite concerns about trial results and dilution.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences ($WVE) is trending due to a proposed offering, sparking concerns of dilution among investors; however, some believe the move is beneficial for the company's long-term prospects after positive data. Community discussions revolve around the potential impact of their drug, WVE-007, on obesity and its competitive edge against GLP-1s.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards as the market reacts to uncertainty around the proposed Warner Bros. Discovery deal, with community members debating whether the acquisition is beneficial and if a competing bid will emerge. Discussions also involve speculation about potential regulatory hurdles and the deal's impact on Netflix's financials. Some traders are seeing a buying opportunity, while others believe the stock is overvalued.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending following news of its inclusion in the S&P 500, driving a surge in stock price and high trading volume. While some investors express enthusiasm and anticipate further gains, others voice concerns about the company's valuation, business practices, and an ongoing SEC investigation, suggesting a potential short opportunity. The community is actively debating whether this rally is sustainable or a 'scam' before a major correction.

SAIHEAT Ltd. engages in the operation of cryptocurrency mining. It operates Bitcoin for its own account and provides full suite of services, purchase of mining machines, hosting service, and mining pool. The company was founded by Risheng Li on February 2, 2021, and is headquartered in Singapore.

SAIHEAT Ltd. - Ordinary Shares - Class A

SAIHEAT Ltd

SAIH is surging as traders circulate unconfirmed rumors about its small modular reactor (SMR) tech being linked to Amazon. The stock's low float and connection to the hot SMR sector, along with potential exposure to both AI and crypto, are fueling speculation of a breakout similar to recent runners. The community is closely watching for a sustained move above key price levels, anticipating a significant price surge.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid discussions about its potential in the GLP-1 space, with the community weighing its prospects against competitors like GPCR and WVE. Community sentiment is mixed, with some expressing frustration over management and market performance, while others maintain confidence in its technology and pipeline, particularly the VK2735 drug. Recent FDA updates on clinical trial requirements are also driving conversation around potential expedited approval pathways.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is surging due to positive topline ACCESS data for its oral GLP-1 aleniglipron, positioning it as a potential competitor in the weight loss market; the community is discussing its potential to reach $100 and comparing it to similar tickers like TGL. Some investors speculate about a possible secondary offering or buyout given the significant price increase and strong data, while others focus on potential safety concerns.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive Phase 1 clinical data for TERN-701, which is being developed for chronic myeloid leukemia, with the community noting the potential to disrupt the CML treatment landscape. Bullish investors are focused on the drug's efficacy and safety profile, while others discuss potential peak sales and acquisition scenarios. However, some traders are wary of the high valuation based on early-stage data and potential for a future offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CRVL
Share Price: $75.21

Contract Selected: Apr 17, 2026 $75 Calls

Buy Zone: $3.82 – $4.73
Target Zone: $7.17 – $8.76
Potential Upside: 77% ROI

Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/

Every trade is a home run. Over 96% win rate on all trades for the past two years, over 1,000,000+ total trades. Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial advice. Trading involves risk, and past performance is not indicative of future results.

Fxcapta

fxcapta.com

StockTwits Web

Corvel Corp.


Share Price: $75.21

Contract Selected: Apr 17, 2026 $75 Calls

Buy Zone: $3.82 – $4.73
Target Zone: $7.17 – $8.76
Potential Upside: 77% ROI

Time to Expiration: 157 Days | Updates via 